

References

Y-5047

1. National Comprehensive Cancer Network. Prostate Cancer. Version 4.2022. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed May 23, 2022.
2. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. *Int J Radiat Oncol Biol Phys*. Jan 01 2008; 70(1): 67-74. PMID 17765406
3. Eade TN, Hanlon AL, Horwitz EM, et al. What dose of external-beam radiation is high enough for prostate cancer?. *Int J Radiat Oncol Biol Phys*. Jul 01 2007; 68(3): 682-9. PMID 17398026
4. Xu N, Rossi PJ, Jani AB. Toxicity analysis of dose escalation from 75.6 gy to 81.0 gy in prostate cancer. *Am J Clin Oncol*. Feb 2011; 34(1): 11-5. PMID 20101167
5. Pisansky TM, Thompson IM, Valicenti RK, et al. Adjuvant and Salvage Radiation Therapy After Prostatectomy: ASTRO/AUA Guideline Amendment, Executive Summary 2018. *Pract Radiat Oncol*. Jul 2019; 9(4): 208-213. PMID 31051281
6. S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on 2021 submission data (1999-2019): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; <https://www.cdc.gov/cancer/dataviz>, released in November 2022. Accessed May 16, 2023.
7. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). *Lancet*. Aug 2005; 366(9485): 572-8. PMID 16099293
8. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. *JAMA*. Nov 15 2006; 296(19): 2329-35. PMID 17105795
9. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. *J Clin Oncol*. Jun 20 2009; 27(18): 2924-30. PMID 19433689
10. Thompson IM, Valicenti RK, Albertsen P, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. *J Urol*. Aug 2013; 190(2): 441-9. PMID 23707439

11. Mishra C. Radiation therapy: which type is right for me? Last reviewed: March 16, 2022. <https://www.oncolink.org/cancer-treatment/radiation/introduction-to-radiation-therapy/radiation-therapy-which-type-is-right-for-me>. Accessed May 23, 2022.
12. Yu T, Zhang Q, Zheng T, et al. The Effectiveness of Intensity Modulated Radiation Therapy versus Three-Dimensional Radiation Therapy in Prostate Cancer: A Meta-Analysis of the Literatures. *PLoS One*. 2016; 11(5): e0154499. PMID 27171271
13. Bauman G, Rumble RB, Chen J, et al. Intensity-modulated radiotherapy in the treatment of prostate cancer. *Clin Oncol (R Coll Radiol)*. Sep 2012; 24(7): 461-73. PMID 22673744
14. Hummel S, Simpson EL, Hemingway P, et al. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. *Health Technol Assess*. Oct 2010; 14(47): 1-108, iii-iv. PMID 21029717
15. Viani GA, Viana BS, Martin JE, et al. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial. *Cancer*. Jul 01 2016; 122(13): 2004-11. PMID 27028170
16. Sujenthiran A, Nossiter J, Charman SC, et al. National Population-Based Study Comparing Treatment-Related Toxicity in Men Who Received Intensity Modulated Versus 3-Dimensional Conformal Radical Radiation Therapy for Prostate Cancer. *Int J Radiat Oncol Biol Phys*. Dec 01 2017; 99(5): 1253-1260. PMID 28974414
17. Michalski JM, Yan Y, Watkins-Bruner D, et al. Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. *Int J Radiat Oncol Biol Phys*. Dec 01 2013; 87(5): 932-8. PMID 24113055
18. Vora SA, Wong WW, Schild SE, et al. Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer. *J Urol*. Aug 2013; 190(2): 521-6. PMID 23415964
19. Wong WW, Vora SA, Schild SE, et al. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy. *Cancer*. Dec 01 2009; 115(23): 5596-606. PMID 19670452
20. Kalbasi A, Li J, Berman A, et al. Dose-Escalated Irradiation and Overall Survival in Men With Nonmetastatic Prostate Cancer. *JAMA Oncol*. Oct 2015; 1(7): 897-906. PMID 26181727
21. Massacesi M, Cilla S, Deodato F, et al. Hypofractionated intensity-modulated radiotherapy with simultaneous integrated boost after radical prostatectomy:

- preliminary results of a phase II trial. *Anticancer Res.* Jun 2013; 33(6): 2785-9. PMID 23749942
22. Alongi F, Fiorino C, Cozzarini C, et al. IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. *Radiother Oncol.* Nov 2009; 93(2): 207-12. PMID 19766338
 23. Leite ETT, Ramos CCA, Ribeiro VAB, et al. Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial. *Int J Radiat Oncol Biol Phys.* Apr 01 2021; 109(5): 1263-1270. PMID 33346091
 24. Katayama S, Habl G, Kessel K, et al. Helical intensity-modulated radiotherapy of the pelvic lymph nodes with integrated boost to the prostate bed - initial results of the PLATIN 3 Trial. *BMC Cancer.* Jan 14 2014; 14: 20. PMID 24422782
 25. Katayama S, Striecker T, Kessel K, et al. Hypofractionated IMRT of the prostate bed after radical prostatectomy: acute toxicity in the PRIAMOS-1 trial. *Int J Radiat Oncol Biol Phys.* Nov 15 2014; 90(4): 926-33. PMID 25216858
 26. Corbin KS, Kunnavakkam R, Eggener SE, et al. Intensity modulated radiation therapy after radical prostatectomy: Early results show no decline in urinary continence, gastrointestinal, or sexual quality of life. *Pract Radiat Oncol.* Apr-Jun 2013; 3(2): 138-44. PMID 24674317
 27. Morgan SC, Hoffman K, Loblaw DA, et al. Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline. *J Urol.* Mar 2019; 201(3): 528-534. PMID 30759696
 28. Nguyen PL, Aizer A, Assimos DG, et al. ACR Appropriateness Criteria(R) Definitive External-Beam Irradiation in stage T1 and T2 prostate cancer. *Am J Clin Oncol.* Jun 2014; 37(3): 278-88. PMID 25180754